INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines

Pomerantz LLP announced that a class-action lawsuit has been filed against ARS Pharmaceuticals (NASDAQ: SPRY). The notice provides no allegations, claimed damages, class period, or company response, but the litigation creates a potential legal and reputational overhang for the biotech company.